NEW YORK, Jan. 4 /PRNewswire-FirstCall/ -- QED International Associates, Inc, administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares Exchange-Traded Funds, today announced that effective at the opening of trading on Monday January 7, 2008, ArQule, Inc. (Nasdaq: ARQL) will replace Coley Pharmaceutical, Inc. (Nasdaq: COLY) in the HealthShares(TM) Emerging Cancer Index. Coley Pharmaceutical is being acquired by Pfizer, Inc. (NYSE: PFE), with 92% of the outstanding shares of COLY tendered under an offer expired December 28, 2007.
Companies included in the HealthShares(TM) Emerging Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers. They generally include those with some level of revenues, or those on the verge of revenues with significant but focused research and development programs.
About QED International Associates
QEDI International, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at http://www.qedinternational.com.
|SOURCE QED International Associates, Inc|
Copyright©2008 PR Newswire.
All rights reserved